Last updated on November 2019

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: prevention & control | HEREDITARY ANGIOEDEMA
  • Age: Between 12 - 100 Years
  • Gender: Male or Female

Key Inclusion Criteria:

  • Subjects with HAE Type I or II who either have participated in a previous BCX7353 study or, in selected countries, in the opinion of the Investigator are expected to derive benefit from an oral treatment for the prevention of angioedema attacks.
  • Access to appropriate medication for treatment of acute attacks
  • Acceptable effective contraception
  • Written informed consent

Key Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study
  • Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study
  • Discontinuation of study drug due to a hypersensitivity reaction BCX7353 in a prior study
  • Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology
  • Unacceptable noncompliance in a previous BCX7353 study (if applicable) as assessed by the Sponsor or Investigator
  • Investigational drug exposure, other than BCX7353, within 30 days prior to the screening visit (or baseline if no screening visit)

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.